13F Pro

SEC Form 4 reporting owner

Sweeny Nicole

Sweeny Nicole has filed 19 Form 4 transactions reported between November 21, 2025 and June 26, 2026, as Director of Monopar Therapeutics and Chief Commercial Officer of KalVista Pharmaceuticals, Inc..

Name as filed: Sweeny Nicole

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$241K
5 lines
Companies
2
with Form 4 filings
Latest transaction
Jun 26, 2026
transaction date

Roles and reported holdings

  • MNPRMonopar Therapeutics
    Jun 26, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KALVKalVista Pharmaceuticals, Inc.
    Nov 21, 2025 – Jun 11, 2026

    Chief Commercial Officer

    Held directly59,291 sh as of May 26, 2026 · Form 4

    24 months: $241K sold

Transaction history

All 19 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 26, 2026MNPRDirectorGrant or awardCode A · direct1,284—Form 4
Jun 11, 2026KALVChief Commercial OfficerDisposition to issuerCode D · direct93,750—Form 4
Jun 11, 2026KALVChief Commercial OfficerDisposition to issuerCode D · direct68,750—Form 4
Jun 11, 2026KALVChief Commercial OfficerDisposition to issuerCode D · direct40,000—Form 4
Jun 11, 2026KALVChief Commercial OfficerDisposition to issuerCode D · direct100,000—Form 4
Jun 11, 2026KALVChief Commercial OfficerDisposition to issuerCode D · direct59,291—Form 4
May 26, 2026KALVChief Commercial OfficerOpen-market saleCode S · direct1,489$40K@ $26.78Form 4
May 22, 2026KALVChief Commercial OfficerOption exerciseCode M · direct5,000—Form 4
May 22, 2026KALVChief Commercial OfficerOpen-market saleCode S · direct1,861$50K@ $26.78Form 4
May 21, 2026KALVChief Commercial OfficerOption exerciseCode M · direct6,250—Form 4
Apr 17, 2026KALVChief Commercial OfficerOpen-market saleCode S · directAlso reported by Piekos Brian1,862$38K@ $20.22Form 4
Apr 16, 2026KALVChief Commercial OfficerOption exerciseCode M · direct6,250—Form 4
Feb 23, 2026KALVChief Commercial OfficerOpen-market saleCode S · direct3,975$62K@ $15.57Form 4
Feb 22, 2026KALVChief Commercial OfficerOption exerciseCode M · direct5,000—Form 4
Feb 21, 2026KALVChief Commercial OfficerOption exerciseCode M · direct6,250—Form 4
Jan 16, 2026KALVChief Commercial OfficerGrant or awardCode A · direct100,000—Form 4
Nov 24, 2025KALVChief Commercial OfficerOpen-market saleCode S · direct3,813$51K@ $13.45Form 4
Nov 22, 2025KALVChief Commercial OfficerOption exerciseCode M · direct5,000—Form 4
Nov 21, 2025KALVChief Commercial OfficerOption exerciseCode M · direct6,250—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.